vimarsana.com

Latest Breaking News On - Cali biosciences - Page 1 : vimarsana.com

Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use

/PRNewswire/ Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali" or "Cali Biosciences"), a biopharmaceutical company focused on the research and.

Cayman islandsSan diegoUnited statesTodd bertochCali biosciences co ltdPrnewswire cali biosciences co ltdCali biosciencesHerniorrhaphy studyTwo pre clinical pipeline products alsoErol onelChief medical officerChief executive officerCali bioscienceHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveries

Cali Biosciences Announces Publications of Phase IIa Results of Long-Acting Ropivacaine (CPL-01)

/PRNewswire/ Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biopharmaceutical company focused on the research and development.

San diegoUnited statesCayman islandsChristine panHanghang tommy xuWilliam nappier cherupIra gottliebLee chenIraj gottliebClinical development centerCali biosciences co ltdAmerican association of pharmaceutical sciences pharmaCali head of clinical research for asiaCali biosciencesPrnewswire cali biosciences co ltdNon opioid treatment

Cali Biosciences Announces Successful Results in Phase IIb Study of Long-Acting Ropivacaine (CPL-01) for Non-Opioid Treatment of Post-Operative Pain

/PRNewswire/ Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biopharmaceutical company focused on the research and development.

San diegoUnited statesCayman islandsTodd bertochClinical development centerCali biosciences co ltdPrnewswire cali biosciences co ltdCali biosciencesErol onelChief medical officerChief executive officerCali bioscienceHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveries

vimarsana © 2020. All Rights Reserved.